BNET Industries

Market Cap:$146.6B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Roche's Merger Formula for Genentech
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
-
EDITORIAL: Difficult mix of business, science
-
$75M verdict unsealed in Prempro-cancer case
-
Sanofi-Aventis on hunt for Boston partners
-
Pfizer says in partnership deal with BMP in China
-
Pfizer Inc. PFE Says in Partnership Deal with BMP Sunstone in China
-
Still Enjoying Those Acquisitions, Pfizer?
-
Status Of Pfizer And Wyeth Research Facilities
-
Monsanto MON Agrees to Acquire Pfizer's PFE Chesterfield Village Research Center for $435M
News & Analysis
Filter by
breast cancer and pfizer inc. - All News and Analysis
PFIZER INC - Research Update.
New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium Pfizer Begins...
Audio from Medialink and Pfizer: A New Way to Prevent Breast Cancer?
To: National DeskTo: National Desk
PFIZER INC - Regulatory Approval.
FDA Approves Pfizer's AromasinR for Adjuvant Treatment of Early Breast Cancer in Postmenopausal Women ...
PFIZER INC - Regulatory Approval.
Pfizer Receives European Approval to Market AromasinR for Adjuvant Treatment of Early Breast Cancer in Postmenopausal Women Aromasin Now the First and Only Hormonal Breast Cancer Drug...
Pfizer Receives European Approval to Market Aromasin(R) for Adjuvant Treatment of Early Breast Cancer in Postmenopausal Women.
NEW YORK, September 13 /PRNewswire/ -- NEW YORK, September 13 /PRNewswire/ --
New Pfizer Drug Improves Odds in Breast Cancer Fight.
By Paul H.B. Shin, Daily News, New York Knight Ridder/Tribune Business News By Paul H.B. Shin, Daily News, New York Knight Ridder/Tribune Business News
Breast Cancer Patients Switched to Pfizer's Aromasin Were More Likely to Remain Cancer Free, Study Shows; Results From Pfizer-Sponsored Study Challenge Standard Tamoxifen Therapy.
Byline: Edelman Public Relations Byline: Edelman Public Relations
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes

